Highlights Intellia Therapeutics, Inc.

Equities

NTLA

US45826J1051

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
24.86 ^USD	+8.09%		+6.83%	-18.47%

02:56pm	Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises	MT
Apr. 15	Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises	08:56am	MT
Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 3 MAGNITUDE Study of NTLA-2001 as Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy	Mar. 18	CI
North American Morning Briefing : Traders Await -2-	Feb. 26	DJ
Intellia Therapeutics Q4 Loss Widens	Feb. 22	MT
Intellia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Intellia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Intellia Therapeutics, ReCode to Develop Therapies For Cystic Fibrosis	Feb. 15	MT
Intellia Therapeutics, Inc. and ReCode Therapeutics Announces Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis	Feb. 15	CI
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine	Jan. 31	CI
Intellia Therapeutics Receives EU Orphan Drug Designation for Hereditary Angioedema Candidate Therapy	Nov. 14	MT
Intellia Therapeutics Shares Fall After Net Loss Narrows, but Revenue Falls in Q3	Nov. 09	MT
Intellia Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Intellia Therapeutics, Inc. Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 At the 4th International ATTR Amyloidosis Meeting	Nov. 02	CI
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy	23-10-18	CI
Intellia Therapeutics, Regeneron Pharmaceuticals Broaden Research Collaboration to Neurological, Muscular Disease Therapies	23-10-03	MT
Regeneron Pharmaceuticals, Inc. and Intellia Therapeutics, Inc. Expands Research Collaboration to Develop Crispr-Based Therapies for the Treatment of Neurological and Muscular Diseases	23-10-03	CI
Intellia Therapeutics Shares Fall After Q2 Net Loss Widens, Revenue Drops	23-08-03	MT
Intellia Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Intellia Therapeutics, Inc. Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema	23-06-11	CI
INTELLIA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	23-05-04	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Intellia Therapeutics, Inc.

Equities

NTLA

US45826J1051

Highlights

Filters